| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Dicer, Drosha, and outcomes in patients with ovarian cancer.
|
N Engl J Med
|
2008
|
8.77
|
|
2
|
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma.
|
Nat Med
|
2006
|
6.18
|
|
3
|
Ovarian cancer.
|
Lancet
|
2009
|
3.95
|
|
4
|
RNA interference in the clinic: challenges and future directions.
|
Nat Rev Cancer
|
2010
|
3.43
|
|
5
|
Regulation of tumor angiogenesis by EZH2.
|
Cancer Cell
|
2010
|
3.10
|
|
6
|
Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.
|
Clin Cancer Res
|
2006
|
2.86
|
|
7
|
Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer.
|
Mol Cancer Ther
|
2010
|
2.27
|
|
8
|
Total laparoscopic radical hysterectomy and lymphadenectomy: the M. D. Anderson Cancer Center experience.
|
Gynecol Oncol
|
2006
|
2.07
|
|
9
|
Neoadjuvant chemotherapy is associated with prolonged primary treatment intervals in patients with advanced epithelial ovarian cancer.
|
Int J Gynecol Cancer
|
2011
|
2.02
|
|
10
|
Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary.
|
Obstet Gynecol
|
2006
|
1.93
|
|
11
|
Lymphatic mapping and sentinel node identification in patients with cervix cancer undergoing radical hysterectomy and pelvic lymphadenectomy.
|
J Clin Oncol
|
2002
|
1.93
|
|
12
|
PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.
|
J Clin Oncol
|
2013
|
1.92
|
|
13
|
Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary.
|
Gynecol Oncol
|
2007
|
1.80
|
|
14
|
Rate of para-aortic lymph node micrometastasis in patients with locally advanced cervical cancer.
|
Gynecol Oncol
|
2010
|
1.77
|
|
15
|
Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.
|
Cancer Biol Ther
|
2010
|
1.71
|
|
16
|
Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.
|
Gynecol Oncol
|
2007
|
1.69
|
|
17
|
Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma.
|
Cancer Res
|
2007
|
1.68
|
|
18
|
Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.
|
Cancer Res
|
2007
|
1.66
|
|
19
|
Lymphatic mapping and sentinel node biopsy in women with high-risk endometrial cancer.
|
Gynecol Oncol
|
2006
|
1.63
|
|
20
|
Therapeutic Targeting of ATP7B in Ovarian Carcinoma.
|
Clin Cancer Res
|
2009
|
1.61
|
|
21
|
Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies.
|
J Clin Oncol
|
2012
|
1.61
|
|
22
|
Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
|
Gynecol Oncol
|
2009
|
1.61
|
|
23
|
A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma.
|
Cancer
|
2010
|
1.61
|
|
24
|
Angiogenesis as a strategic target for ovarian cancer therapy.
|
Nat Clin Pract Oncol
|
2008
|
1.57
|
|
25
|
Clinical and biological significance of tissue transglutaminase in ovarian carcinoma.
|
Cancer Res
|
2008
|
1.55
|
|
26
|
The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.
|
Clin Cancer Res
|
2012
|
1.54
|
|
27
|
Clinical and biological significance of vascular endothelial growth factor in endometrial cancer.
|
Clin Cancer Res
|
2007
|
1.51
|
|
28
|
Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer.
|
Cancer Biol Ther
|
2009
|
1.47
|
|
29
|
Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group study.
|
J Clin Oncol
|
2012
|
1.46
|
|
30
|
Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial.
|
Cancer
|
2010
|
1.46
|
|
31
|
Conservative surgery in early-stage cervical cancer: what percentage of patients may be eligible for conization and lymphadenectomy?
|
Gynecol Oncol
|
2010
|
1.46
|
|
32
|
Usefulness of preoperative lymphoscintigraphy in patients who undergo radical hysterectomy and pelvic lymphadenectomy for cervical cancer.
|
Am J Obstet Gynecol
|
2006
|
1.45
|
|
33
|
Functional significance of VEGFR-2 on ovarian cancer cells.
|
Int J Cancer
|
2009
|
1.39
|
|
34
|
Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma.
|
Cancer Res
|
2006
|
1.38
|
|
35
|
Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer.
|
Cancer Biol Ther
|
2006
|
1.38
|
|
36
|
EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma.
|
J Natl Cancer Inst
|
2009
|
1.37
|
|
37
|
Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma.
|
Clin Cancer Res
|
2007
|
1.34
|
|
38
|
Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial.
|
Cancer Chemother Pharmacol
|
2003
|
1.33
|
|
39
|
Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study.
|
Cancer
|
2011
|
1.33
|
|
40
|
Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer.
|
Cancer
|
2010
|
1.32
|
|
41
|
Dual targeting of EphA2 and FAK in ovarian carcinoma.
|
Cancer Biol Ther
|
2009
|
1.30
|
|
42
|
SGO White Paper on ovarian cancer: etiology, screening and surveillance.
|
Gynecol Oncol
|
2010
|
1.27
|
|
43
|
A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies.
|
Clin Cancer Res
|
2011
|
1.26
|
|
44
|
Impact of vessel maturation on antiangiogenic therapy in ovarian cancer.
|
Am J Obstet Gynecol
|
2008
|
1.25
|
|
45
|
Farletuzumab in epithelial ovarian carcinoma.
|
Expert Opin Biol Ther
|
2010
|
1.21
|
|
46
|
Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum.
|
Gynecol Oncol
|
2008
|
1.19
|
|
47
|
Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.
|
Gynecol Oncol
|
2013
|
1.18
|
|
48
|
Tumor board: more than treatment planning--a 1-year prospective survey.
|
J Cancer Educ
|
2008
|
1.17
|
|
49
|
Management strategies for recurrent platinum-resistant ovarian cancer.
|
Drugs
|
2011
|
1.17
|
|
50
|
EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer.
|
Cancer
|
2009
|
1.13
|
|
51
|
Antitumor and antivascular effects of AVE8062 in ovarian carcinoma.
|
Cancer Res
|
2007
|
1.11
|
|
52
|
Laparoscopic extraperitoneal para-aortic lymphadenectomy in locally advanced cervical cancer: a prospective correlation of surgical findings with positron emission tomography/computed tomography findings.
|
Cancer
|
2010
|
1.09
|
|
53
|
Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death.
|
J Natl Cancer Inst
|
2011
|
1.08
|
|
54
|
Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker.
|
Cancer
|
2010
|
1.07
|
|
55
|
Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer.
|
Lancet Oncol
|
2010
|
1.06
|
|
56
|
Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer.
|
Cancer Res
|
2011
|
1.05
|
|
57
|
Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer.
|
Cancer Biol Ther
|
2010
|
1.04
|
|
58
|
Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.
|
Mol Cancer Ther
|
2010
|
1.04
|
|
59
|
Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma.
|
Cancer Biol Ther
|
2009
|
1.04
|
|
60
|
Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth.
|
Clin Cancer Res
|
2008
|
1.04
|
|
61
|
Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors.
|
Invest New Drugs
|
2012
|
1.03
|
|
62
|
Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer.
|
Clin Cancer Res
|
2011
|
1.03
|
|
63
|
Nodal metastasis risk in endometrioid endometrial cancer.
|
Obstet Gynecol
|
2012
|
1.02
|
|
64
|
Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma.
|
Mol Cancer Ther
|
2010
|
1.02
|
|
65
|
The use of adjuvant radiation therapy in early endometrial cancer by members of the Society of Gynecologic Oncologists in 2005.
|
Gynecol Oncol
|
2006
|
1.02
|
|
66
|
Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds.
|
Int J Gynecol Cancer
|
2009
|
1.00
|
|
67
|
Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer.
|
Gynecol Oncol
|
2005
|
0.99
|
|
68
|
A double-blind, randomized, placebo-controlled phase III study of the safety of alvimopan in patients who undergo simple total abdominal hysterectomy.
|
Am J Obstet Gynecol
|
2006
|
0.97
|
|
69
|
Risk of thromboembolic disease in patients undergoing laparoscopic gynecologic surgery.
|
Obstet Gynecol
|
2010
|
0.97
|
|
70
|
EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma.
|
Clin Cancer Res
|
2010
|
0.95
|
|
71
|
A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study.
|
Gynecol Oncol
|
2011
|
0.95
|
|
72
|
Analysis of prognostic factors for patients with leiomyoma treated with uterine arterial embolization.
|
Am J Obstet Gynecol
|
2007
|
0.95
|
|
73
|
Chemosensitivity testing with ChemoFx and overall survival in primary ovarian cancer.
|
Am J Obstet Gynecol
|
2010
|
0.93
|
|
74
|
Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer.
|
Gynecol Oncol
|
2008
|
0.93
|
|
75
|
Adenosquamous histology predicts poor outcome in low-risk stage IB1 cervical adenocarcinoma.
|
Gynecol Oncol
|
2003
|
0.93
|
|
76
|
Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer.
|
Gynecol Oncol
|
2007
|
0.91
|
|
77
|
Primary neuroendocrine carcinoma of the vagina with Merkel cell carcinoma phenotype.
|
Am J Surg Pathol
|
2006
|
0.90
|
|
78
|
A phase II trial of paclitaxel and carboplatin in women with advanced or recurrent uterine carcinosarcoma.
|
Int J Gynecol Cancer
|
2011
|
0.90
|
|
79
|
Stage IIB-IVB cervical adenocarcinoma: prognostic factors and survival.
|
Gynecol Oncol
|
2002
|
0.90
|
|
80
|
Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies.
|
Gynecol Oncol
|
2004
|
0.89
|
|
81
|
Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.
|
Cancer Metastasis Rev
|
2015
|
0.89
|
|
82
|
Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.
|
Gynecol Oncol
|
2012
|
0.89
|
|
83
|
Electrothermal bipolar coagulation for pelvic exenterations.
|
Gynecol Oncol
|
2006
|
0.89
|
|
84
|
Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors.
|
Gynecol Oncol
|
2009
|
0.89
|
|
85
|
Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications.
|
Cancer Metastasis Rev
|
2015
|
0.89
|
|
86
|
Contemporary use of bevacizumab in ovarian cancer.
|
Expert Opin Biol Ther
|
2012
|
0.88
|
|
87
|
Venous thromboembolism (VTE) rates following the implementation of extended duration prophylaxis for patients undergoing surgery for gynecologic malignancies.
|
Gynecol Oncol
|
2012
|
0.88
|
|
88
|
Adenosquamous carcinoma versus adenocarcinoma in early-stage cervical cancer patients undergoing radical hysterectomy: an outcomes analysis.
|
Gynecol Oncol
|
2007
|
0.86
|
|
89
|
Lymphatic mapping and sentinel lymph node detection in women with vaginal cancer.
|
Gynecol Oncol
|
2008
|
0.86
|
|
90
|
Moving beyond anti-vascular endothelial growth factor therapy in ovarian cancer.
|
J Clin Oncol
|
2011
|
0.85
|
|
91
|
Investigational agents in development for the treatment of ovarian cancer.
|
Invest New Drugs
|
2012
|
0.85
|
|
92
|
Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study.
|
Gynecol Oncol
|
2011
|
0.85
|
|
93
|
Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
|
Gynecol Oncol
|
2005
|
0.84
|
|
94
|
The role of maintenance therapy and novel taxanes in ovarian cancer.
|
Gynecol Oncol
|
2006
|
0.84
|
|
95
|
Aflibercept in epithelial ovarian carcinoma.
|
Future Oncol
|
2009
|
0.84
|
|
96
|
Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer.
|
Gynecol Oncol
|
2012
|
0.83
|
|
97
|
P16 as a molecular biomarker of cervical adenocarcinoma.
|
Am J Obstet Gynecol
|
2004
|
0.83
|
|
98
|
Surgical staging of ovarian low malignant potential tumors.
|
Obstet Gynecol
|
2004
|
0.83
|
|
99
|
Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009.
|
Int J Gynecol Cancer
|
2010
|
0.83
|
|
100
|
Targeting SRC and tubulin in mucinous ovarian carcinoma.
|
Clin Cancer Res
|
2013
|
0.83
|
|
101
|
Preoperative factors predicting survival after secondary cytoreduction for recurrent ovarian cancer.
|
Int J Gynecol Cancer
|
2011
|
0.83
|
|
102
|
Unmet needs in ovarian cancer: dividing histologic subtypes to exploit novel targets and pathways.
|
Curr Cancer Drug Targets
|
2013
|
0.82
|
|
103
|
Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib.
|
Clin Cancer Res
|
2014
|
0.82
|
|
104
|
Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer.
|
Gynecol Oncol
|
2004
|
0.82
|
|
105
|
Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube.
|
Gynecol Oncol
|
2012
|
0.82
|
|
106
|
Supracervical hysterectomy in patients with advanced epithelial ovarian cancer.
|
Obstet Gynecol
|
2007
|
0.81
|
|
107
|
The search continues: looking for predictive biomarkers for response to mammalian target of rapamycin inhibition in endometrial cancer.
|
Int J Gynecol Cancer
|
2014
|
0.81
|
|
108
|
Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model.
|
J Oncol Pharm Pract
|
2007
|
0.81
|
|
109
|
Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer.
|
Curr Pharm Des
|
2012
|
0.81
|
|
110
|
Sister Society Meeting on Global Education Development and Collaboration: Meeting Report.
|
Int J Gynecol Cancer
|
2016
|
0.81
|
|
111
|
Evaluation of pegylated liposomal doxorubicin dose on the adverse drug event profile and outcomes in treatment of recurrent endometrial cancer.
|
Int J Gynecol Cancer
|
2013
|
0.80
|
|
112
|
Targeting angiogenesis in gynecologic cancers.
|
Hematol Oncol Clin North Am
|
2012
|
0.79
|
|
113
|
Vintafolide: a novel targeted agent for epithelial ovarian cancer.
|
Future Oncol
|
2014
|
0.79
|
|
114
|
CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan.
|
Gynecol Oncol
|
2006
|
0.79
|
|
115
|
Summary of the 2014 MD Anderson International Meeting in Gynecologic Oncology: emerging therapies in gynecologic cancer.
|
Gynecol Oncol
|
2014
|
0.78
|
|
116
|
A comprehensive pelvic dissection course improves obstetrics and gynecology resident proficiency in surgical anatomy.
|
Am J Obstet Gynecol
|
2003
|
0.78
|
|
117
|
A case-control study of methylenetetrahydrofolate reductase polymorphisms in cervical carcinogenesis.
|
Gynecol Oncol
|
2005
|
0.78
|
|
118
|
New ways to successfully target tumor vasculature in ovarian cancer.
|
Curr Opin Obstet Gynecol
|
2015
|
0.77
|
|
119
|
Other primary malignancies in patients with uterine corpus malignancy.
|
Am J Obstet Gynecol
|
2004
|
0.77
|
|
120
|
Primary vaginal melanoma: a rare and problematic clinical entity.
|
Ann Surg Oncol
|
2004
|
0.77
|
|
121
|
Defining the role of echinocandin catechol functional groups in the development of secondary hepatocellular carcinoma.
|
J Antimicrob Chemother
|
2011
|
0.77
|
|
122
|
Therapeutic advances in women's cancers.
|
Front Biosci (Schol Ed)
|
2011
|
0.76
|
|
123
|
Primary peritoneal serous carcinoma presenting as inflammatory breast cancer.
|
Breast J
|
2009
|
0.76
|
|
124
|
Endocervical curettage at conization to predict residual cervical adenocarcinoma in situ.
|
Gynecol Oncol
|
2002
|
0.76
|
|
125
|
Acquiring laparoscopic skill proficiency: does orientation matter?
|
Am J Obstet Gynecol
|
2004
|
0.75
|
|
126
|
Erythropoeisis-stimulating agents (ESAs) in cervix cancer: The "black box" paradox.
|
Cancer Biol Ther
|
2009
|
0.75
|
|
127
|
Intraperitoneal chemotherapy for frontline ovarian cancer therapy: vindicated or vilified?
|
Curr Oncol Rep
|
2006
|
0.75
|
|
128
|
Role of appendectomy at the time of primary surgery in patients with early-stage ovarian cancer.
|
Gynecol Oncol
|
2006
|
0.75
|
|
129
|
Lymphatic mapping for vulvar cancer: ready for "prime-time?".
|
Curr Oncol Rep
|
2008
|
0.75
|
|
130
|
Vulvar lymphatic mapping: coming of age?
|
Ann Surg Oncol
|
2002
|
0.75
|
|
131
|
Gemcitabine plus carboplatin compared with carboplatin alone for platinum-sensitive recurrent ovarian cancer.
|
Curr Oncol Rep
|
2007
|
0.75
|
|
132
|
Emerging therapeutics for primary peritoneal cancer.
|
Expert Opin Emerg Drugs
|
2011
|
0.75
|
|
133
|
Foreword.
|
Gynecol Oncol
|
2016
|
0.75
|
|
134
|
Emerging therapeutic options for platinum-sensitive ovarian cancer patients.
|
Clin Adv Hematol Oncol
|
2011
|
0.75
|
|
135
|
Selected highlights from the 5th International Conference on Ovarian Cancer. Houston, TX, USA, 1-4 December 2004.
|
Expert Opin Pharmacother
|
2005
|
0.75
|
|
136
|
Reported cystoscopic experience correlates poorly with objective assessment of cystoscopic skills.
|
Female Pelvic Med Reconstr Surg
|
2012
|
0.75
|
|
137
|
Lymph node counts in uterine cancer: a randomized double blind trial.
|
Gynecol Oncol
|
2009
|
0.75
|
|
138
|
Management of low-risk gestational trophoblastic neoplasia in indigent women.
|
J Reprod Med
|
2003
|
0.75
|
|
139
|
Cervical adenocarcinoma survival among Hispanic and white women: a multicenter cohort study.
|
Am J Obstet Gynecol
|
2003
|
0.75
|
|
140
|
Targeted therapy in gynecologic oncology: biology, strategy, and assessment.
|
Gynecol Oncol
|
2010
|
0.75
|
|
141
|
A feasibility study of carboplatin and weekly paclitaxel combination chemotherapy in endometrial cancer: a Kansai Clinical Oncology Group study (KCOG0015 trial).
|
Gynecol Oncol
|
2010
|
0.75
|
|
142
|
Proceedings from the 9th International Conference on Ovarian Cancer.
|
Gynecol Oncol
|
2011
|
0.75
|
|
143
|
Laparoscopic colostomy in gynecologic cancer.
|
J Minim Invasive Gynecol
|
2008
|
0.75
|
|
144
|
Role of Video-Assisted Thoracoscopy in Advanced Ovarian Cancer: A Literature Review.
|
Int J Gynecol Cancer
|
2016
|
0.75
|